menu
    • menu
    [{"orgOrder":0,"company":"National Heart, Lung, and Blood Institute","sponsor":"Institute for Transfusion Medicine | Versiti | Blood Centers of the Pacific | American National Red Cross | University of California, San Francisco | Vitalant Research Institute | RTI International","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2012","type":"Inapplicable","leadProduct":"Ferrous Gluconate","moa":"Transferrin receptor protein 1; Egl nine homolog 1; Histone deacetylase 8; Alpha-hemoglobin-stabilizing protein; Hemoglobin subunit alpha; Frataxin, mitochondrial; Ferritin heavy chain; Flap endonuclease 1; Endonuclease 8-like 1; Endonuclease 8-like 2; DNA polymerase beta; Ceruloplasmin; Serotransferrin","graph1":"Undisclosed","graph2":"Phase II","graph3":"National Heart, Lung, and Blood Institute","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"National Heart, Lung, and Blood Institute \/ Institute for Transfusion Medicine | Versiti | Blood Centers of the Pacific | American National Red Cross | University of California, San Francisco | Vitalant Research Institute | RTI International","highestDevelopmentStatusID":"8","companyTruncated":"National Heart, Lung, and Blood Institute \/ Institute for Transfusion Medicine | Versiti | Blood Centers of the Pacific | American National Red Cross | University of California, San Francisco | Vitalant Research Institute | RTI International"},{"orgOrder":0,"company":"Dar\u00e9 Bioscience","sponsor":"Avomeen","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Partnership","leadProduct":"Ferrous Gluconate","moa":"||Transferrin receptor protein 1; Egl nine homolog 1; Histone deacetylase 8; Alpha-hemoglobin-stabilizing protein; Hemoglobin subunit alpha; Frataxin, mitochondrial; Ferritin heavy chain; Flap endonuclease 1; Endonuclease 8-like 1; Endonuclease 8-like 2; DNA polymerase beta; Ceruloplasmin; Serotransferrin","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Dar\u00e9 Bioscience","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Implant","sponsorNew":"Dar\u00e9 Bioscience \/ Avomeen","highestDevelopmentStatusID":"15","companyTruncated":"Dar\u00e9 Bioscience \/ Avomeen"},{"orgOrder":0,"company":"Dar\u00e9 Bioscience","sponsor":"Bayer AG","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2022","type":"Inapplicable","leadProduct":"Ferrous Gluconate","moa":"||Transferrin receptor protein 1; Egl nine homolog 1; Histone deacetylase 8; Alpha-hemoglobin-stabilizing protein; Hemoglobin subunit alpha; Frataxin, mitochondrial; Ferritin heavy chain; Flap endonuclease 1; Endonuclease 8-like 1; Endonuclease 8-like 2; DNA polymerase beta; Ceruloplasmin; Serotransferrin","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Dar\u00e9 Bioscience","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Implant","sponsorNew":"Dar\u00e9 Bioscience \/ Bayer AG","highestDevelopmentStatusID":"15","companyTruncated":"Dar\u00e9 Bioscience \/ Bayer AG"},{"orgOrder":0,"company":"Dar\u00e9 Bioscience","sponsor":"Bill & Melinda Gates Foundation","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2024","type":"Funding","leadProduct":"Ferrous Gluconate","moa":"||Transferrin receptor protein 1; Egl nine homolog 1; Histone deacetylase 8; Alpha-hemoglobin-stabilizing protein; Hemoglobin subunit alpha; Frataxin, mitochondrial; Ferritin heavy chain; Flap endonuclease 1; Endonuclease 8-like 1; Endonuclease 8-like 2; DNA polymerase beta; Ceruloplasmin; Serotransferrin","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Dar\u00e9 Bioscience","amount2":0.01,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0.01,"dosageForm":"Implant","sponsorNew":"Dar\u00e9 Bioscience \/ Bill & Melinda Gates Foundation","highestDevelopmentStatusID":"15","companyTruncated":"Dar\u00e9 Bioscience \/ Bill & Melinda Gates Foundation"},{"orgOrder":0,"company":"Dar\u00e9 Bioscience","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2020","type":"Inapplicable","leadProduct":"Ferrous Gluconate","moa":"Transferrin receptor protein 1; Egl nine homolog 1; Histone deacetylase 8; Alpha-hemoglobin-stabilizing protein; Hemoglobin subunit alpha; Frataxin, mitochondrial; Ferritin heavy chain; Flap endonuclease 1; Endonuclease 8-like 1; Endonuclease 8-like 2; DNA polymerase beta; Ceruloplasmin; Serotransferrin","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Dar\u00e9 Bioscience","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Implant","sponsorNew":"Dar\u00e9 Bioscience \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Dar\u00e9 Bioscience \/ Undisclosed"},{"orgOrder":0,"company":"Dar\u00e9 Bioscience","sponsor":"XOMA","pharmaFlowCategory":"D","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2024","type":"Financing","leadProduct":"Ferrous Gluconate","moa":"||Transferrin receptor protein 1; Egl nine homolog 1; Histone deacetylase 8; Alpha-hemoglobin-stabilizing protein; Hemoglobin subunit alpha; Frataxin, mitochondrial; Ferritin heavy chain; Flap endonuclease 1; Endonuclease 8-like 1; Endonuclease 8-like 2; DNA polymerase beta; Ceruloplasmin; Serotransferrin","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Approved FDF","graph3":"Dar\u00e9 Bioscience","amount2":0.02,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0.02,"dosageForm":"Implant","sponsorNew":"Dar\u00e9 Bioscience \/ XOMA","highestDevelopmentStatusID":"15","companyTruncated":"Dar\u00e9 Bioscience \/ XOMA"},{"orgOrder":0,"company":"Westat","sponsor":"Versiti | American National Red Cross | The Institute for Transfusion Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2014","type":"Inapplicable","leadProduct":"Ferrous Gluconate","moa":"Transferrin receptor protein 1; Egl nine homolog 1; Histone deacetylase 8; Alpha-hemoglobin-stabilizing protein; Hemoglobin subunit alpha; Frataxin, mitochondrial; Ferritin heavy chain; Flap endonuclease 1; Endonuclease 8-like 1; Endonuclease 8-like 2; DNA polymerase beta; Ceruloplasmin; Serotransferrin","graph1":"Hematology","graph2":"Undisclosed","graph3":"Westat","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Pill","sponsorNew":"Westat \/ Versiti | American National Red Cross | The Institute for Transfusion Medicine","highestDevelopmentStatusID":"1","companyTruncated":"Westat \/ Versiti | American National Red Cross | The Institute for Transfusion Medicine"}]

    Find Clinical Drug Pipeline Developments & Deals for Ferrous Gluconate

    Menu

    Ferrous Gluconate

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    GLOBAL SALES INFORMATION

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Daré Bioscience

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Daré Bioscience

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ferrous Gluconate,Ascorbic Acid

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Phase III

                            Sponsor : Bill & Melinda Gates Foundation

                            Deal Size : $10.7 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Daré Gets Grant to Expand Ovaprene® Study & Develop Non-Hormonal Contraceptive

                            Details : The proceeds will fund the development to accelerate the ongoing Ovaprene (ferrous gluconate & ascorbic acid), a novel, hormone-free monthly intravaginal contraceptive, pivotal study.

                            Product Name : Ovaprene

                            Product Type : Vitamins/Minerals/Inorganic Salts

                            Upfront Cash : Undisclosed

                            November 13, 2024

                            Lead Product(s) : Ferrous Gluconate,Ascorbic Acid

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Phase III

                            Sponsor : Bill & Melinda Gates Foundation

                            Deal Size : $10.7 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Daré Bioscience

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Daré Bioscience

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ferrous Gluconate,Ascorbic Acid

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Phase III

                            Sponsor : XOMA

                            Deal Size : $22.0 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Dar© Secures $22M Royalty Financing for Women's Health Product Candidates

                            Details : Proceeds will advance Ovaprene, an intravaginal contraceptive ring, and Sildenafil Cream, a potential FDA-approved treatment for female sexual arousal disorder.

                            Product Name : Ovaprene

                            Product Type : Vitamins/Minerals/Inorganic Salts

                            Upfront Cash : Undisclosed

                            April 30, 2024

                            Lead Product(s) : Ferrous Gluconate,Ascorbic Acid

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Phase III

                            Sponsor : XOMA

                            Deal Size : $22.0 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Daré Bioscience

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Daré Bioscience

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ferrous Gluconate,Ascorbic Acid

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Approved FDF

                            Sponsor : Bayer AG

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Daré Bioscience Announces IDE Approval for a Single Arm, Open-Label Pivotal Contraceptive Efficacy Study of O...

                            Details : Ovaprene®, an investigational hormone-free monthly intravaginal contraceptive, prevented essentially all sperm from entering the cervical canal across all women and all cycles evaluated.

                            Product Name : Ovaprene

                            Product Type : Vitamins/Minerals/Inorganic Salts

                            Upfront Cash : Inapplicable

                            October 10, 2022

                            Lead Product(s) : Ferrous Gluconate,Ascorbic Acid

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Approved FDF

                            Sponsor : Bayer AG

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Daré Bioscience

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Daré Bioscience

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ferrous Gluconate,Ascorbic Acid

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Phase III

                            Sponsor : Avomeen

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Daré Bioscience and Avomeen Form Strategic Partnership to Accelerate the Development of Daré’s Novel Pipel...

                            Details : Daré and Avomeen are currently collaborating on development-stage programs, including Ovaprene®, an investigational hormone-free, monthly contraceptive, and intend to expand their partnership to include more programs in Daré’s women’s health pipel...

                            Product Name : Ovaprene

                            Product Type : Vitamins/Minerals/Inorganic Salts

                            Upfront Cash : Undisclosed

                            September 01, 2020

                            Lead Product(s) : Ferrous Gluconate,Ascorbic Acid

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Phase III

                            Sponsor : Avomeen

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Daré Bioscience

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Daré Bioscience

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ferrous Gluconate

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Daré Bioscience Reports Use of the Postcoital Test Study as a Predictor of Contraceptive Effectiveness by Bio...

                            Details : Publication of a literature review article by Biology of Reproduction identifies and reviews 10 postcoital test studies of vaginal contraceptives involving 9 test products, including Daré’s Ovaprene, currently under a license agreement with Bayer.

                            Product Name : Ovaprene

                            Product Type : Vitamins/Minerals/Inorganic Salts

                            Upfront Cash : Inapplicable

                            June 24, 2020

                            Lead Product(s) : Ferrous Gluconate

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Westat

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Westat

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ferrous Gluconate

                            Therapeutic Area : Hematology

                            Study Phase : Undisclosed

                            Sponsor : Versiti | American National Red Cross | The Institute for Transfusion Medicine

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Strategies to Reduce Iron Deficiency

                            Details : Ferrous Gluconate is a Vitamins/Minerals/Inorganic Salts drug candidate, which is currently being evaluated in clinical studies for the treatment of Iron Deficiencies.

                            Product Name : Undisclosed

                            Product Type : Vitamins/Minerals/Inorganic Salts

                            Upfront Cash : Inapplicable

                            September 19, 2014

                            Lead Product(s) : Ferrous Gluconate

                            Therapeutic Area : Hematology

                            Highest Development Status : Undisclosed

                            Sponsor : Versiti | American National Red Cross | The Institute for Transfusion Medicine

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            National Heart, Lung, and Blood Institute

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            National Heart, Lung, and Blood Institute

                            Country arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ferrous Gluconate

                            Therapeutic Area : Undisclosed

                            Study Phase : Phase II

                            Sponsor : Institute for Transfusion Medicine | Versiti | Blood Centers of the Pacific | American National Red Cross | University of California, San Francisco | Vitalant Research Institute | RTI International

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Hemoglobin and Iron Recovery Study

                            Details : Ferrous Gluconate is a Vitamins/Minerals/Inorganic Salts drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Recovery of Hemoglobin and Iron Stores.

                            Product Name : Undisclosed

                            Product Type : Vitamins/Minerals/Inorganic Salts

                            Upfront Cash : Inapplicable

                            March 15, 2012

                            Lead Product(s) : Ferrous Gluconate

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Phase II

                            Sponsor : Institute for Transfusion Medicine | Versiti | Blood Centers of the Pacific | American National Red Cross | University of California, San Francisco | Vitalant Research Institute | RTI International

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth